A Phase 4 interventional study of Motilitone ® and Pantoline® in Functional Dyspepsia, sponsored by Dong-A ST Co., Ltd.. Completed at 1 site in Korea, Republic of. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2015-01-27.
Sponsored by Dong-A ST Co., Ltd. · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies in Dyspepsia with a site in Korea, Republic of — 3 open to participants now, 4 under way, none of them phase 3. Dyspepsia · Korea, Republic of.
Among the 28 studies in Dyspepsia with a site in Korea, Republic of, this one is the 2nd largest by enrollment of the 26 interventional ones that give a count, is the only one that started in 2012, is one of 8 in phase 4, and was the 3rd registered.
372 studies on the registry are indexed under Dyspepsia; 66 are open to participants now.
Browse Dyspepsia studies →3 of the 28 studies in Dyspepsia with a site in Korea, Republic of are open now. Recruiting first, the newest first:
Dong-A ST Co., Ltd. · Sites in Korea, Republic of
Ages 19–75
Myungmoon Pharma. Co. Ltd. · Sites in Korea, Republic of
Ages 19+
Seoul National University Bundang Hospital · Sites in Korea, Republic of
Ages 19+ · Healthy volunteers
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 46 Dyspepsia studies recruiting now, 16 (35%) set no upper age limit and 23 (50%) stop at 75 or younger; 2 take children under 18; 8 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2 · Phase 3 4 · Phase 4 8
First in 2009; this study’s year is marked. 1 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 389 is above the median of 89 across 302 interventional studies indexed under Dyspepsia.
Median enrollment 100 across the 26 interventional studies, 206 across the 2 observational. Of the 17 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 28 have an industry lead sponsor. The 10 most frequent:
Dong-A ST Co., Ltd. is the lead sponsor of 122 studies on the registry; 9 are open to participants now.
Dong-A ST Co., Ltd. has 4 studies filed under Dyspepsia — fewer than ten, so there is no comparison to draw.
2 of the studies in Dyspepsia with a site in Korea, Republic of that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07686679Dong-A ST Co., Ltd.A Study to Evaluate the Efficacy and Safety of DA-9701 in Patients With Functional Dyspepsia | 2027-10 |
| NCT07016269Myungmoon Pharma. Co. Ltd.A Study to Evaluate the Efficacy and Safety of CnU Cap. 500 mg in Patients With Biliary Dyspepsia | 2027-11-10 |
Add all 2 to your calendar (.ics) → With an account.
Among the 28 studies in Dyspepsia with a site in Korea, Republic of, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a phase IV , comparative study to evaluate the efficacy and safety of Motiltone® in treatment of the patients with functional dyspepsia. The study is conducted with following methods: multi-centers, double blind, randomization, parallel. The subjects will receive Motilitone® or/and Pantoline®.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
30 mg is administered with a tablet of placebo (Pantoline®)
Drug: Motilitone ®
40mg is administered with a tablet of Motilitone®
Drug: Pantoline®
Both drugs are administered at once
Drug: Motilitone® and Pantoline®
Subject global assessment by using 5-Likert scale and Binary outcome methods
5-Likert scale: 0: worse 1. similar 2. improved in some degree 3. considerably improved 4. completely cured Binary outcome: yes/no
Time frame: 6 weeks
Number of dyspepsia(indigestion) symptoms occurred (Counted daily)
Time frame: 6 weeks
Assessment of NDI-K Quality of Life
Time frame: 6 weeks
Soreness of digestive symptoms (dyspepsia) evaluated its intensity on a scale of 1 to 5
Time frame: 6 weeks
The record gives a start of Aug 2012, a primary completion of Mar 2014 and a completion of Mar 2014. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: DA-9701